Your browser doesn't support javascript.
loading
Cerebral dopamine neurotrophic factor reduces α-synuclein aggregation and propagation and alleviates behavioral alterations in vivo.
Albert, Katrina; Raymundo, Diana P; Panhelainen, Anne; Eesmaa, Ave; Shvachiy, Liana; Araújo, Gabriela R; Chmielarz, Piotr; Yan, Xu; Singh, Aastha; Cordeiro, Yraima; Palhano, Fernando L; Foguel, Debora; Luk, Kelvin C; Domanskyi, Andrii; Voutilainen, Merja H; Huttunen, Henri J; Outeiro, Tiago F; Saarma, Mart; Almeida, Marcius S; Airavaara, Mikko.
Afiliación
  • Albert K; Institute of Biotechnology, HiLIFE, University of Helsinki, 00014 Helsinki, Finland.
  • Raymundo DP; Instituto de Bioquímica Médica Leopoldo de Meis, Universidade Federal do Rio de Janeiro, Rio de Janeiro 21.941-902, Brazil; Department of Experimental Neurodegeneration, Center for Biostructural Imaging of Neurodegeneration, University Medical Center Göttingen, 37073 Göttingen, Germany; Protein Adva
  • Panhelainen A; Institute of Biotechnology, HiLIFE, University of Helsinki, 00014 Helsinki, Finland; Faculty of Pharmacy, University of Helsinki, Helsinki, Finland.
  • Eesmaa A; Institute of Biotechnology, HiLIFE, University of Helsinki, 00014 Helsinki, Finland.
  • Shvachiy L; Department of Experimental Neurodegeneration, Center for Biostructural Imaging of Neurodegeneration, University Medical Center Göttingen, 37073 Göttingen, Germany; Centro Cardiovascular da Universidade de Lisboa, Faculdade de Medicina, Universidade de Lisboa, Av Prof Egas Moniz, 1649-028 Lisbon, Por
  • Araújo GR; Instituto de Bioquímica Médica Leopoldo de Meis, Universidade Federal do Rio de Janeiro, Rio de Janeiro 21.941-902, Brazil; Protein Advanced Biochemistry, CENABIO, Universidade Federal do Rio de Janeiro, Rio de Janeiro 21.941-902, Brazil.
  • Chmielarz P; Institute of Biotechnology, HiLIFE, University of Helsinki, 00014 Helsinki, Finland; Department of Brain Biochemistry, Maj Institute of Pharmacology, Polish Academy of Sciences, Krakow 31-343, Poland.
  • Yan X; Neuroscience Center, HiLIFE, University of Helsinki, 00014 Helsinki, Finland.
  • Singh A; Institute of Biotechnology, HiLIFE, University of Helsinki, 00014 Helsinki, Finland.
  • Cordeiro Y; Faculdade de Farmácia, Universidade Federal do Rio de Janeiro, Rio de Janeiro 21.941-902, Brazil.
  • Palhano FL; Instituto de Bioquímica Médica Leopoldo de Meis, Universidade Federal do Rio de Janeiro, Rio de Janeiro 21.941-902, Brazil.
  • Foguel D; Instituto de Bioquímica Médica Leopoldo de Meis, Universidade Federal do Rio de Janeiro, Rio de Janeiro 21.941-902, Brazil.
  • Luk KC; Center for Neurodegenerative Disease Research, Department of Pathology and Laboratory Medicine, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA 19104, USA.
  • Domanskyi A; Institute of Biotechnology, HiLIFE, University of Helsinki, 00014 Helsinki, Finland.
  • Voutilainen MH; Institute of Biotechnology, HiLIFE, University of Helsinki, 00014 Helsinki, Finland; Faculty of Pharmacy, University of Helsinki, Helsinki, Finland.
  • Huttunen HJ; Neuroscience Center, HiLIFE, University of Helsinki, 00014 Helsinki, Finland; Herantis Pharma Plc, 20520 Espoo, Finland.
  • Outeiro TF; Department of Experimental Neurodegeneration, Center for Biostructural Imaging of Neurodegeneration, University Medical Center Göttingen, 37073 Göttingen, Germany; Max Planck Institute for Experimental Medicine, 37075 Göttingen, Germany; Institute of Neuroscience, The Medical School, Newcastle Unive
  • Saarma M; Institute of Biotechnology, HiLIFE, University of Helsinki, 00014 Helsinki, Finland.
  • Almeida MS; Instituto de Bioquímica Médica Leopoldo de Meis, Universidade Federal do Rio de Janeiro, Rio de Janeiro 21.941-902, Brazil; Protein Advanced Biochemistry, CENABIO, Universidade Federal do Rio de Janeiro, Rio de Janeiro 21.941-902, Brazil. Electronic address: msalmeida@cenabio.ufrj.br.
  • Airavaara M; Institute of Biotechnology, HiLIFE, University of Helsinki, 00014 Helsinki, Finland; Neuroscience Center, HiLIFE, University of Helsinki, 00014 Helsinki, Finland; Faculty of Pharmacy, University of Helsinki, Helsinki, Finland. Electronic address: mikko.airavaara@helsinki.fi.
Mol Ther ; 29(9): 2821-2840, 2021 09 01.
Article en En | MEDLINE | ID: mdl-33940158
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Enfermedad de Parkinson / Sustancia Negra / Alfa-Sinucleína / Factores de Crecimiento Nervioso Tipo de estudio: Prognostic_studies Límite: Animals / Humans / Male Idioma: En Revista: Mol Ther Asunto de la revista: BIOLOGIA MOLECULAR / TERAPEUTICA Año: 2021 Tipo del documento: Article País de afiliación: Finlandia Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Enfermedad de Parkinson / Sustancia Negra / Alfa-Sinucleína / Factores de Crecimiento Nervioso Tipo de estudio: Prognostic_studies Límite: Animals / Humans / Male Idioma: En Revista: Mol Ther Asunto de la revista: BIOLOGIA MOLECULAR / TERAPEUTICA Año: 2021 Tipo del documento: Article País de afiliación: Finlandia Pais de publicación: Estados Unidos